Discover the top 26 companies transforming the liquid biopsy market, including Natera, Inc., Guardant Health, Myriad Genetics, Inc., and other industry leaders. Backed by a market projected to grow from $4.03B to $7.05B by 2030 at a CAGR of 11.8%, this analysis highlights competitive strengths, breakthrough innovations, and strategic moves shaping the future of the industry. Access the full market research report for deeper insights.

Download PDF Brochure:“Click Here”

Spotlights on the Industry’s Top Liquid Biopsy Companies

Natera, Inc.

Natera, Inc. is a global leader in cell-free DNA (cfDNA) testing, specializing in women’s health, oncology, and organ health. Headquartered in Austin, Texas, the company utilizes a proprietary technology platform that combines advanced molecular biology with bioinformatics and AI to detect genetic material down to a single molecule. Its prominent product portfolio includes the Panorama non-invasive prenatal test (NIPT), the Signatera molecular residual disease (MRD) assay for individualized cancer monitoring, and the Prospera test for transplant rejection assessment. Natera operates CAP-accredited and CLIA-certified laboratories and has significantly expanded its clinical impact with over 15 million tests processed and hundreds of peer-reviewed publications validating its technology.

Guardant Health

Guardant Health is a leading precision oncology company dedicated to conquering cancer through the use of proprietary liquid biopsy tests, vast data sets, and advanced analytics. Based in Palo Alto, California, the company offers a suite of non-invasive blood tests, including Guardant360 for genomic profiling in advanced-stage cancer, Guardant Reveal for monitoring residual disease in early-stage patients, and Shield for colorectal cancer screening. Guardant Health’s oncology platform is designed to support the entire cancer care continuum, from screening and early detection to therapy selection and recurrence monitoring. With a strong focus on innovation, the company continues to expand its technology capabilities through strategic acquisitions and partnerships with biopharmaceutical leaders.

Myriad Genetics, Inc.

Myriad Genetics, Inc. is a prominent genetic testing and precision medicine company headquartered in Salt Lake City, Utah. Since its founding in 1991, Myriad has pioneered the development of molecular diagnostic tests that assess disease risk, predict progression, and guide treatment decisions across medical specialties including oncology, urology, reproductive health, and mental health. The company’s core offerings include the MyRisk Hereditary Cancer test, the Prolaris prostate cancer prognostic assay, and the GeneSight pharmacogenomics test for mental health medication selection. By leveraging its “Lab of the Future” and extensive clinical data, Myriad provides actionable genetic insights aimed at improving patient outcomes and reducing overall healthcare costs.

Illumina, Inc.

Illumina, Inc. is the global leader in DNA sequencing and array-based technologies, providing the foundational tools for genomics research and clinical diagnostics. The company’s comprehensive portfolio of sequencing systems, including the NovaSeq and NextSeq platforms, enables large-scale genomic analysis and has been instrumental in the development of liquid biopsy and non-invasive prenatal testing. Illumina’s technology supports a wide range of applications from oncology and reproductive health to infectious disease and complex disease research. Through continuous innovation in chemistry and informatics, Illumina remains a critical driver of the precision medicine movement, empowering laboratories worldwide to decode the genome with increasing speed and accuracy.

F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd. is a global healthcare pioneer in both pharmaceuticals and diagnostics, with a significant presence in the liquid biopsy market through its Roche Diagnostics division. The company offers advanced molecular testing solutions, including the AVENIO ctDNA assays, which utilize next-generation sequencing to provide comprehensive genomic profiling from blood samples. Roche focuses on integrating diagnostic insights with personalized medicine, particularly in oncology, to help clinicians select the most effective therapies for cancer patients. By combining its deep expertise in biotechnology with cutting-edge diagnostic platforms, Roche continues to lead in the development of tools for therapy monitoring and minimal residual disease detection.

Qiagen N.V.

Qiagen N.V. is a leading global provider of Sample to Insight solutions that enable customers to derive valuable molecular insights from biological samples. In the liquid biopsy sector, Qiagen offers specialized kits and technologies for the stabilization, extraction, and analysis of circulating cell-free DNA and RNA from blood. Its portfolio includes the therascreen companion diagnostic platform and digital PCR systems like the QIAcuity, which provide high sensitivity for detecting rare cancer mutations. Qiagen’s solutions are widely used in clinical research and diagnostics to support liquid biopsy workflows, facilitating the transition toward more flexible and minimally invasive patient monitoring.

Exact Sciences Corporation

Exact Sciences Corporation is a leading cancer diagnostics company best known for its non-invasive screening test, Cologuard, for colorectal cancer. The company has expanded its focus into the liquid biopsy market with a robust pipeline of blood-based tests for early cancer detection and molecular residual disease (MRD) monitoring. Through strategic acquisitions like Thrive and Ashion, Exact Sciences is developing multi-cancer early detection (MCED) technologies aimed at identifying multiple cancer types from a single blood draw. The company’s mission is to provide life-changing innovations that enable earlier cancer detection and more informed treatment guidance, leveraging its commercial scale and laboratory infrastructure.

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. is a world leader in serving science, providing a broad range of analytical instruments, equipment, and reagents for life sciences research and diagnostics. The company is a major player in the liquid biopsy market through its Ion Torrent next-generation sequencing (NGS) platforms and Oncomine assays, which are designed for highly sensitive detection of somatic mutations in liquid biopsy samples. Thermo Fisher’s solutions provide end-to-end workflows that enable clinical researchers and healthcare providers to perform comprehensive genomic profiling and therapy monitoring. The company focuses on expanding the accessibility of liquid biopsy technology through automated systems and standardized clinical assays.

GRAIL, Inc.

GRAIL, Inc., a subsidiary of Illumina, is a healthcare company whose mission is to detect cancer early when it can be cured. The company has developed Galleri, a pioneering multi-cancer early detection (MCED) blood test that can detect more than 50 types of cancer before symptoms appear. Galleri uses next-generation sequencing and machine-learning algorithms to analyze methylation patterns in cell-free DNA, identifying the presence of a cancer signal and predicting the tissue of origin. GRAIL is focused on large-scale clinical trials and population-scale studies to validate its technology and integrate early cancer screening into routine healthcare, potentially transforming the standard of cancer care.

Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. is a global leader in developing and manufacturing a broad range of products for the life science research and clinical diagnostic markets. In the liquid biopsy space, Bio-Rad is a pioneer in Droplet Digital PCR (ddPCR) technology, which provides absolute quantification of target DNA molecules with high sensitivity and precision. Its ddPCR systems are widely utilized for the detection and monitoring of rare genetic mutations and molecular residual disease (MRD) in oncology. Bio-Rad’s commitment to providing reliable and highly accurate molecular tools supports researchers and clinicians in advancing liquid biopsy applications for cancer management and personalized medicine.

Sysmex Corporation

Sysmex Corporation is a Japanese company specializing in laboratory testing equipment and diagnostics, with a growing focus on “personalized medicine” through its liquid biopsy solutions. The company utilizes advanced technologies such as OncoBeam and Plasma-Safe-SeqS to detect rare genetic mutations in blood samples with high sensitivity. Sysmex’s liquid biopsy portfolio supports the selection of targeted therapies and the monitoring of treatment response in cancer patients. Through its subsidiary Sysmex Inostics, the company provides comprehensive clinical laboratory services and kits that facilitate the adoption of blood-based genomic testing in oncology practices worldwide.

mdxhealth

mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient care in urology. The company’s liquid biopsy offerings, such as Select mdx for Prostate Cancer, use non-invasive biomarkers to help clinicians assess the risk of aggressive disease and determine the necessity of a prostate biopsy. mdxhealth focuses on improving the diagnosis and treatment of prostate and other urologic cancers, aiming to reduce unnecessary procedures and improve patient outcomes through advanced genomic testing. The company leverages its proprietary epigenetic and molecular platforms to deliver high-quality, clinically validated diagnostic tests.

Personalis, Inc.

Personalis, Inc. is a leader in advanced genomics for cancer, providing large-scale sequencing and data analysis for clinical research and diagnostics. The company’s Neogenomics liquid biopsy platform, Neogenomics, utilizes an “exome-wide” approach to monitor minimal residual disease (MRD) and therapy response with high sensitivity. Personalis focuses on providing comprehensive genomic insights by analyzing thousands of genetic variants from a single blood sample, allowing for a more complete understanding of tumor evolution and resistance. The company partners with biopharmaceutical firms and clinical investigators to accelerate the development of personalized cancer therapies and improve precision oncology outcomes.

The Menarini Group

The Menarini Group is an international pharmaceutical and diagnostics company that has established a significant presence in the liquid biopsy market through its Menarini Silicon Biosystems division. The company is known for its CellSearch technology, which is the first and only FDA-cleared system for the capture and enumeration of circulating tumor cells (CTCs). Menarini also offers the DEPArray system for precise, single-cell sorting and analysis. These technologies enable clinicians and researchers to study the heterogeneity of cancer at the cellular level from a blood draw, providing critical insights for therapy selection and disease monitoring in oncology.

NeoGenomics Laboratories

NeoGenomics Laboratories is a leading oncology-focused clinical laboratory providing a comprehensive menu of diagnostic, prognostic, and predictive testing services. The company offers a variety of liquid biopsy solutions, including next-generation sequencing panels and molecular residual disease (MRD) assays, designed to detect cancer-related mutations in circulating cell-free DNA. NeoGenomics supports community oncologists, hospitals, and biopharmaceutical companies by delivering high-quality genomic data that informs treatment decisions and clinical trial eligibility. Its extensive laboratory network and expertise in cancer pathology make it a key provider of integrated diagnostic solutions in the precision oncology space.

ANGLE plc

ANGLE plc is a world-leading liquid biopsy company that has developed a patented microfluidic technology, Parsortix, for the capture and harvesting of intact circulating tumor cells (CTCs) from blood. Unlike systems that rely on surface markers, the Parsortix system captures CTCs based on their size and compressibility, allowing for the isolation of a wide range of cancer cell types. ANGLE’s technology enables subsequent molecular and cellular analysis, including protein expression and genetic profiling. The company focuses on providing a “liquid biopsy” alternative to traditional tissue biopsies, supporting personalized cancer management and the development of new diagnostic applications.

Labcorp Holdings Inc.

Labcorp Holdings Inc. is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through its Labcorp Oncology division, the company offers an extensive portfolio of liquid biopsy tests, including the Labcorp Plasma Focus NGS panel for comprehensive genomic profiling. Labcorp leverages its massive laboratory infrastructure and clinical expertise to provide accessible blood-based testing for therapy selection and disease monitoring. The company’s integrated approach combines diagnostic testing with drug development services, playing a critical role in advancing precision medicine and improving cancer care delivery.

Bio-Techne

Bio-Techne is a global life sciences company that provides innovative tools and bioactive reagents for the research and clinical diagnostic communities. In the liquid biopsy market, the company’s Exosome Diagnostics division is a leader in exosome-based molecular testing. Their ExoDx Prostate test is a non-invasive, urine-based liquid biopsy that analyzes exosomal RNA to help clinicians determine the risk of high-grade prostate cancer. Bio-Techne focuses on leveraging the unique biological information contained in exosomes to develop highly sensitive diagnostics for various cancers and other diseases, providing a complementary approach to traditional cell-free DNA testing.

Mesa Labs, Inc.

Mesa Labs, Inc. is a global technology company that provides critical quality control solutions for the pharmaceutical, healthcare, and industrial markets. Through its acquisition of Agena Bioscience, Mesa Labs entered the liquid biopsy and clinical genomics space with the MassARRAY System. This platform utilizes highly sensitive mass spectrometry for the detection of genetic variants and is widely used for liquid biopsy applications, including the monitoring of cancer mutations from circulating cell-free DNA. Mesa Labs focuses on providing scalable and cost-effective molecular testing solutions that enable laboratories to deliver high-throughput, accurate results for personalized medicine.

MedGenome

MedGenome is a leading genomics and precision medicine company with a primary focus on emerging markets, particularly South Asia. The company provides a comprehensive range of genetic testing services, including advanced liquid biopsy solutions for oncology. MedGenome’s liquid biopsy platform uses next-generation sequencing to detect actionable mutations and monitor treatment response in various cancer types. By integrating clinical data with genomic insights from diverse populations, MedGenome aims to accelerate drug discovery and improve the management of complex diseases. The company partners with global biopharmaceutical firms and healthcare providers to expand the reach of precision diagnostics.

LungLife AI, Inc.

LungLife AI, Inc. is a developer of clinical diagnostic solutions designed to improve the early detection of lung cancer. The company’s lead product, LungLB, is a liquid biopsy test that utilizes a proprietary artificial intelligence platform to identify rare, circulating abnormal cells in the blood of individuals with indeterminate lung nodules. LungLife AI focuses on providing clinicians with actionable information to help determine which nodules are likely to be cancerous, potentially reducing unnecessary invasive procedures and speeding up the path to treatment. The company’s technology emphasizes the integration of advanced cell imaging with machine learning for high-precision lung cancer assessment.

Strand

Strand Life Sciences is a specialized genomics and bioinformatics company that provides advanced diagnostic testing and research services, with a strong emphasis on oncology. Their liquid biopsy portfolio includes multi-gene NGS panels designed to detect circulating tumor DNA (ctDNA) for therapy selection and minimal residual disease (MRD) monitoring. Strand leverages its deep expertise in data science and clinical genomics to deliver comprehensive reports that help oncologists personalize patient care. The company operates high-throughput, accredited laboratories and serves a global clientele, focusing on providing affordable and high-quality precision medicine solutions in the Indian and international markets.

Vortex Biotech Holdings

Vortex Biotech Holdings is an innovative liquid biopsy company that has developed a proprietary microfluidic technology for the rapid and label-free isolation of circulating tumor cells (CTCs). Their Vortex VMS system utilizes physical forces to trap larger, less deformable cancer cells from whole blood while allowing smaller blood cells to pass through. This approach enables the collection of high-purity, viable CTCs for downstream analysis, including genomics and transcriptomics. Vortex focuses on providing a powerful tool for cancer research and clinical diagnostics that overcomes the limitations of marker-dependent capture methods, facilitating a more comprehensive study of metastatic cancer.

Freenome Holdings, Inc.

Freenome Holdings, Inc. is a biotechnology company that combines molecular biology with machine learning to develop blood tests for early cancer detection. The company’s multiomics platform analyzes various biological signals, including cell-free DNA, methylation, and proteins, to identify the early signatures of cancer. Freenome’s initial focus is on the early detection of colorectal cancer through its PREEMPT CRC study, with plans to expand into other cancer types. By integrating diverse biological data through advanced AI, Freenome aims to provide highly accurate and accessible screening tools that can detect cancer at its most treatable stages.

Lucence Health Inc.

Lucence Health Inc. is a precision oncology company that develops ultra-sensitive liquid biopsy tests for cancer screening and monitoring. Their flagship LiquidHALLMARK test is a comprehensive NGS assay that detects mutations, fusions, and viral loads across a wide range of cancer types from a single blood draw. Lucence utilizes its proprietary AmpliMARK technology to achieve high sensitivity and specificity, providing clinicians with actionable data for therapy selection and resistance monitoring. Headquartered in Palo Alto and Singapore, the company focuses on delivering personalized cancer insights to patients and physicians globally, particularly in the Asian and US markets.

New Day Diagnostics, LLC

New Day Diagnostics, LLC is a healthcare company focused on the development and commercialization of affordable and accessible diagnostic tests for early disease detection. The company has a growing presence in the liquid biopsy sector through its focus on developing blood-based biomarkers for various cancers, including colorectal cancer. New Day Diagnostics aims to streamline the diagnostic pathway by providing easy-to-use testing solutions that can be integrated into routine clinical workflows. Through strategic partnerships and a commitment to innovation, the company works to improve patient outcomes by enabling earlier intervention and more effective disease management.

Download PDF Brochure:“Click Here”